Abstract
Amiodarone is a drug commonly used to treat and prevent cardiac arrhythmias, but it is often associated with several adverse effects, the most serious of which is pulmonary toxicity. A 79-year-old man presented with respiratory failure due to interstitial pneumonia during the COVID-19 pandemic. The viral etiology was nevertheless excluded by repeated nasopharyngeal swabs and serological tests and the final diagnosis was amiodarone-induced organizing pneumonia. The clinical and computed tomography findings improved after amiodarone interruption and steroid therapy. Even during a pandemic, differential diagnosis should always be considered and pulmonary toxicity has to be taken into account in any patient taking amiodarone and who has new respiratory symptoms.
Original language | English |
---|---|
Pages (from-to) | 991-997 |
Number of pages | 7 |
Journal | Future Cardiology |
Volume | 17 |
DOIs | |
Publication status | Published - 2021 |
Keywords
- Aged
- Amiodarone
- Anti-Arrhythmia Agents
- COVID-19
- Diagnosis, Differential
- Humans
- Lung Diseases, Interstitial
- Male
- Pandemics
- SARS-CoV-2
- Tomography, X-Ray Computed
- amiodarone
- coronavirus
- differential diagnosis
- drug toxicity
- interstitial pneumonia
- organizing pneumonia